CAS: 1776116-74-5

MC1742 inhibits class I/IIb HDACs, blocks sarcoma CSC growth, and reactivates latent HIV. IC50: HDAC1-3/8 (0.02-0.61 μM), HDAC6/10 (7-40 nM).

MC 1742 is a drug that has been shown to be effective in the treatment of demyelinating diseases such as multiple sclerosis. MC 1742 is a cytotoxic agent that targets and kills immature oligodendrocytes, which are cells that produce myelin sheaths. MC 1742 is a potent inhibitor of HIV-1 latency in mesenchymal stem cells and also induces reactivation of latent HIV-1 from resting CD4+ T cells.